PFE Pfizer Inc.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.…
Industry Peers
Drug Manufacturers - GeneralKey Statistics
About Pfizer (NYSE: PFE)
›
Pfizer (NYSE: PFE) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Drug Manufacturers - General industry, part of the Healthcare sector, and reports about 75,000 employees.
The shares were at 27.54 USD on 19 November 2026, up 13.6% over 52 weeks. Its 52-week range is 23.62 USD to 31.44 USD: the price is 12.4% below the high and 16.6% above the low.
At a market capitalisation of 156.97B USD, it trades at 39.3 times trailing earnings and 9.3 times forward earnings. The median trailing P/E of its 19 largest Drug Manufacturers - General peers is 25.4, a premium of 55% for PFE. It pays a dividend yielding 6.13% (it pays out 246% of its earnings), against a median of 2.43% among the dividend payers in that peer group.
Pfizer reports return on equity of 9.0%, an operating margin of 29.1% and flat revenue year over year.
Its debt exceeds its cash by 49.13B USD, a debt-to-equity ratio of 0.74. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 26 analysts cover the stock, with an average rating of Hold; their mean price target of 30.22 USD is 9.7% above the current price. The next earnings report is expected on 2 February 2027.